HDAC9 and pancreatic neoplasm: We chose mocetinostat as our model HDAC inhibitor because prior preclinical studies have shown synergy with gemcitabine [52] as measured by in vitro growth inhibition and apoptosis of PANC1 and BxPC3 pancreatic cancer cells.